Friday, May 1, 2026

Peaceful Time is Over: Is Coexistence the New Path for South Korea?

Experts urge South Korea to shift from unification to coexistence with North Korea, focusing on practical peace amid rising tensions.

Trial of Ex-Defense Chiefs Yeo and Moon Set to Intensify in Martial Law Crisis Case

The trial of former military chiefs Yeo In Hyeong and Moon Sang Ho intensifies over their roles in the December 3 martial law crisis.

President Lee says policy of peaceful coexistence on Korean Peninsula will remain steady, expects response from North Korea

President Lee Jae-myung emphasizes peaceful coexistence on the Korean Peninsula, urging inter-Korean trust and stability despite challenges.

Tag: Celltrion

North KoreaKoreaKimMilitarySouth KoreaAImarketrelationsInternational

How Celltrion Plans to Cut Biologics Development Costs by 25% Amid FDA Regulation Changes

Celltrion is optimistic about enhanced competitiveness due to eased biosimilar regulations by the FDA, expecting significant cost reductions.

Celltrion’s CT-P55: What Changes to FDA Clinical Trials Mean for Biosimilarity with Cosentyx?

Celltrion has applied to the FDA for changes to its Phase 3 trial of CT-P55, reducing participants to 153 to assess biosimilarity to Cosentyx.

Celltrion’s Ramucirumab and Infliximab: The Secrets Behind Their Dominance in Oceania’s Biopharmaceutical Market

Celltrion's cancer and autoimmune products are expanding market share in Australia and New Zealand, enhancing influence in Oceania.

How Celltrion’s Herceptin Biosimilar Herzuma Achieved 74% Market Share in Japan: A Game Changer for Cancer Treatment

Celltrion's Herzuma biosimilar captures 74% of Japan's trastuzumab market, enhancing patient access and leveraging favorable policies.

Celltrion’s Strategic Move: How Local Production in the U.S. Can Mitigate Tariff Risks

Celltrion outlines its Branchburg facility's operations and plans to mitigate tariff risks by establishing local production and a supply system.

CT-P55: How Celltrion’s New Biosimilar Approval Will Transform Clinical Trials in Europe

Celltrion receives EMA approval to reduce patient enrollment for CT-P55 trial, aiming to cut costs and duration of clinical development.

Celltrion’s Remsima Surpasses 1 Trillion KRW in Sales for 2nd Consecutive Year: What’s Driving Its Success?

Celltrion's Remsima treatment surpasses 1 trillion KRW in sales, driven by European market growth and new liquid formulation.

Celltrion Gets Global IB Upgrades: Morgan Stanley Raises Target to $206.25 as New Biosimilars Lift Margins

Celltrion is expanding through biosimilars and new drug development, attracting global investor interest and raising target stock prices.

How Celltrion’s Omlyclo is Dominating Spain’s Omalizumab Market: A First-Mover Success Story

Celltrion's Omlyclo treatment is thriving in Spain, capturing over 60% of the omalizumab market with innovative strategies and strong demand.

Celltrion’s Remsima SC: The Leading Autoimmune Drug with 68% Market Share in Europe

Celltrion's treatments for autoimmune diseases and cancer maintain strong market positions in Europe, bolstered by stable prescriptions and new products.

Celltrion’s Zymfentra: How This Breakthrough Drug is Driving Record Sales

Celltrion expects record sales driven by Zymfentra's success, expanding into new biosimilars and CDMO business for future growth.

How Celltrion is Tackling U.S. Tariff Risks with New Production Facility in 2026

Celltrion addresses tariff risks by acquiring a U.S. facility, ensuring product supply and implementing strategies to mitigate uncertainties.

How Celltrion Plans to Expand Its Biosimilar Portfolio to 41 Products by 2038

Celltrion unveils its growth strategy at the JP Morgan Healthcare Conference, aiming to expand biosimilars and develop new drug pipelines.

K-Bio Targets the U.S. Market: Celltrion and Samsung Bioepis Close in on Originator Drugs

Celltrion and Samsung Bioepis are expanding in the U.S. market, showing strong growth in biosimilars like Zymfentra and Hadlima.

Top News

- Our Sponsors Ad -

Follow us

Cars

Tech

future

health

© Copyright by News1. All Rights Reserved.